Peter DeMuth
Direttore Tecnico/Scientifico/R&S presso ELICIO THERAPEUTICS, INC.
Patrimonio netto: - $ in data 30/04/2024
Profilo
Peter DeMuth is currently the Chief Scientific Officer at Elicio Therapeutics, Inc. He started this position in 2022.
He holds a doctorate degree from the Massachusetts Institute of Technology, which he received in 2013.
He also has an undergraduate degree from the University of Maryland, which he obtained in 2008.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ELICIO THERAPEUTICS, INC
-.--% | 01/02/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Posizioni attive di Peter DeMuth
| Società | Posizione | Inizio |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2022 |
Precedenti posizioni note di Peter DeMuth
| Società | Posizione | Fine |
|---|---|---|
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/06/2023 |
Formazione di Peter DeMuth
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Maryland | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ELICIO THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Peter DeMuth
